Les publications

Page en cours de mise à jour... Retrouvez ici les publications des équipes de recherche du CGO

452 publications
Année de publication :
Réseaux :

Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis.

In most autoimmune disorders, crosstalk of B cells and CD4 T cells results in the accumulation of autoantibodies. In autoimmune hepatitis (AIH), the presence of anti-soluble liver antigen (SLA) autoantibodies is associated with reduced overall survival, but the associated autoreactive CD4 T cells have not yet been characterised.

  • Ref: J Hepatol. 2020 Dec;73(6):1379-1390.
  • Année de publication : 2020
  • Auteurs : Renand A, Cervera-Marzal I, Gil L, Dong C, Garcia A, Kervagoret E, Aublé H, Habes S, Chevalier C, Vavasseur F, Clémenceau B, Cardon A, Judor JP, Mosnier JF, Tanné F, Laplaud DA, Brouard S, Gournay J, Milpied P, Conchon S.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Accuracy of peritoneal carcinomatosis extent diagnosis by initial FDG PET CT in epithelial ovarian cancer: A…

Peritoneal carcinomatosis extent in ovarian cancer is difficult to evaluate by imaging techniques even though it determines the surgical complexity and survival. The aim of this study was to estimate the accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-PET CT (Positron-emission tomography coupled with Computerised Tomography) performed before any treatment, in the diagnosis of the extent of peritoneal carcinomatosis.

  • Ref: J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101867.
  • Année de publication : 2020
  • Auteurs : Delvallée J, Rossard L, Bendifallah S, Touboul C, Collinet P, Bricou A, Huchon C, Lavoue V, Body G, Ouldamer L.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Sarcoma treatment in the era of molecular medicine.

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies.

  • Ref: EMBO Mol Med. 2020 Nov 6;12(11):e11131.
  • Année de publication : 2020
  • Auteurs : Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-Aranaz F, Di Pompo G, Distel M, Dorado-Garcia H, Garcia-Castro J, González-González L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-Esquivel C, Morales-Molina Á, Musa J, Ohmura S, Ory B, Pereira-Silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-Jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Involvement of GPx-3 in the Reciprocal Control of Redox Metabolism in the Leukemic Niche.

The bone marrow (BM) microenvironment plays a crucial role in the development and progression of leukemia (AML). Intracellular reactive oxygen species (ROS) are involved in the regulation of the biology of leukemia-initiating cells, where the antioxidant enzyme GPx-3 could be involved as a determinant of cellular self-renewal.

  • Ref: Int J Mol Sci. 2020 Nov 14;21(22):8584.
  • Année de publication : 2020
  • Auteurs : Vignon C, Debeissat C, Bourgeais J, Gallay N, Kouzi F, Anginot A, Picou F, Guardiola P, Ducrocq E, Foucault A, Ravalet N, Le Nail LR, Domenech J, Béné MC, Le Bousse-Kerdilès MC, Gyan E, Herault O.
  • Réseaux : Réseaux: « Niches et Epigénétique des Tumeurs »
Lire la publication

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study.

Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibition was more efficacious than immune checkpoint inhibition alone in patients with previously untreated BRAFV600 wild-type advanced melanoma.

  • Ref: Ann Oncol. 2020 Dec 10:S0923-7534(20)43203-X.
  • Année de publication : 2020
  • Auteurs : Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Francesco Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, Yan Y, Castro M, Mulla S, Flaherty K, Arance A.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1…

Background: Clinical benefit from programmed cell death 1 receptor (PD-1) inhibitors relies on reinvigoration of endogenous antitumor immunity. Nonetheless, robust immunological markers, based on circulating immune cell subsets associated with therapeutic efficacy are yet to be validated.

  • Ref: J Immunother Cancer. 2020 Nov;8(2):e001631.
  • Année de publication : 2020
  • Auteurs : Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Macrophages: Checking Toxicity of Fungal Metabolites in the Colon.

It is well known that the intestine absorbs nutrients, electrolytes, and water. Chikina et al. recently demonstrated that it is also able to sense, recognize, and block the absorption of toxins through a very sophisticated interactive cellular cooperation between novel subpopulations of macrophages and epithelial cells.

  • Ref: Trends Endocrinol Metab. 2020 Dec 17:S1043-2760(20)30248-4.
  • Année de publication : 2020
  • Auteurs : Blatzer M, Papon N, Delneste Y, Latgé JP.
  • Réseaux : Réseaux: « Immunothérapies »
Lire la publication

Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with…

Purpose: Report results of the phase Ib dose-escalation/expansion study of triplet therapy with cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor (ribociclib), mTOR inhibitor (everolimus), and endocrine therapy (exemestane).

  • Ref: Clin Cancer Res. 2020 Dec 15;26(24):6417-6428.
  • Année de publication : 2020
  • Auteurs : Bardia A, Modi S, Oliveira M, Cortes J, Campone M, Ma B, Dirix L, Weise A, Hewes B, Diaz-Padilla I, Han Y, Deshpande P, Samant TS, Lorenc KR, He W, Su F, Chavez-MacGregor M.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast…

Many patients with HR+, HER2- early breast cancer (EBC) will not experience recurrence or have distant recurrence with currently available standard therapies. However, up to 30% of patients with high-risk clinical and/or pathologic features may experience distant recurrence, many in the first few years.

  • Ref: J Clin Oncol. 2020 Dec 1;38(34):3987-3998.
  • Année de publication : 2020
  • Auteurs : Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators.
  • Réseaux : Réseaux: « Cancers des Tissus Hormono-dépendants »
Lire la publication